EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

NTRK Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy

Vicente R Marczyk iD, Sasan Fazeli iD, Ramona Dadu, Naifa L Busaidy iD, Priyanka Iyer, Mimi I Hu iD, Steven I Sherman iD, Sarah Hamidi iD, Sayed Mohsen Hosseini iD, Michelle D Williams iD, Salmaan Ahmed, Mark J Routbort iD und 10 weitere

JCO Precision Oncology · 2025-07 · (9)

DOI: 10.1200/po.24.00321 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JCO Precision Oncology, 2025-07. Verfasst von Vicente R Marczyk und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Receptor, trkA, Receptor, trkC, Thyroid Cancer, Papillary. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Neurotrophic tropomyosin receptor kinase ( NTRK ) fusions may act as an oncogenic driver in thyroid carcinomas. Given their low frequency, clinical, pathological, and molecular data on these patients and their responses to targeted therapies are limited. METHODS This is an observational retrospective study conducted at a single high-volume cancer center in the United States. Data were retrospectively collected from medical records. RESULTS We included 65 patients (37 adult, 28 pediatric) with an NTRK fusion–positive thyroid carcinoma (24 NTRK1 , 41 NTRK3 ), of which 54 were papillary thyroid carcinomas (PTC), four poorly differentiated thyroid carcinomas (PDTC), and seven anaplastic thyroid carcinomas (ATC). In PTC, an extensive follicular growth pattern was seen in 22 (41%) patients. In adults, NTRK3 fusions were 3 times more frequent (nine NTRK1 , 28 NTRK3 ), whereas in pediatric patients their frequencies were similar (15 NTRK1 , 13 NTRK3 ; P = .021). In patients with PDTC/ATC treated with larotrectinib, we detected four emergent solvent front mutations (three NTRK3 G623R, one NTRK1 G595R) causing resistance to drug and disease progression. Three of them (two ATC, one PDTC) received second-line selitrectinib on a clinical trial. Partial responses were seen in all three patients, but both patients with ATC progressed within a year. CONCLUSION NTRK1 / 3 fusions are seen in PTC, PDTC, and ATC, and a follicular growth pattern was observed in a high proportion of cases. In patients treated with larotrectinib, NTRK solvent front mutations are the main resistance mechanism, frequently occurring in PDTC/ATC. Responses to single-agent TRK inhibitor are short-lived in patients with ATC; thus, these drugs should be used with caution in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsReceptor, trkAReceptor, trkCThyroid Cancer, PapillaryHumansFemaleMaleRetrospective StudiesAdultMiddle AgedChildAgedAdolescentPyrazolesMolecular Targeted TherapyYoung AdultPyrimidines

Substanzen

Receptor, trkAReceptor, trkCNTRK3 protein, humanNTRK1 protein, humanlarotrectinibPyrazolesPyrimidines

Autor:innen und Institutionen

  • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX.
  • Department of Pathology, The University of Texas MD Anderson Cancer, Houston, TX.
  • Department of Neuroradiology, The University of Texas MD Anderson Cancer, Houston, TX.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer, Houston, TX.
  • Clinical Bioinformatics, The University of Texas MD Anderson Cancer, Houston, TX.
  • Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer, Houston, TX.

ORCID-Profile: Vicente R Marczyk, Sasan Fazeli, Naifa L Busaidy, Mimi I Hu, Steven I Sherman, Sarah Hamidi, Sayed Mohsen Hosseini, Michelle D Williams, Mark J Routbort, Raja Luthra, Sinchita Roy-Chowdhuri, Keyur P Patel, David S Hong, Mark Zafereo, Jennifer R Wang, Anastasios Maniakas, Steven G Waguespack, Maria E Cabanillas

Förderung

  • NCI NIH HHS

Zitieren

APA

Marczyk, V. R., Fazeli, S., Dadu, R., Busaidy, N. L., Iyer, P., Hu, M. I., Sherman, S. I., Hamidi, S., Hosseini, S. M., Williams, M. D., Ahmed, S., Routbort, M. J., Luthra, R., Roy-Chowdhuri, S., San Lucas, F. A., Patel, K. P., Hong, D. S., Zafereo, M., Wang, J. R., …, & Cabanillas, M. E. (2025). NTRK Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy. JCO Precision Oncology. https://doi.org/10.1200/po.24.00321

Vancouver

Marczyk VR, Fazeli S, Dadu R, Busaidy NL, Iyer P, Hu MI, et al. NTRK Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy. JCO Precision Oncology. 2025. doi:10.1200/po.24.00321

BibTeX
@article{Marczyk2025,
  author = {Marczyk, Vicente R and Fazeli, Sasan and Dadu, Ramona and Busaidy, Naifa L and Iyer, Priyanka and Hu, Mimi I and Sherman, Steven I and Hamidi, Sarah and Hosseini, Sayed Mohsen and Williams, Michelle D and Ahmed, Salmaan and Routbort, Mark J and Luthra, Raja and Roy-Chowdhuri, Sinchita and San Lucas, Francis Anthony and Patel, Keyur P and Hong, David S and Zafereo, Mark and Wang, Jennifer R and Maniakas, Anastasios and Waguespack, Steven G and Cabanillas, Maria E},
  title = {NTRK Fusion–Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po.24.00321}
}
Kostenlos starten →